Biology:ICOSLG

From HandWiki
Revision as of 08:00, 12 February 2024 by Carolyn (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

ICOS ligand is a protein that in humans is encoded by the ICOSLG gene[1][2][3] located at chromosome 21. ICOSLG has also been designated as CD275 (cluster of differentiation 275).

ICOSLG is glycosylated transmembrane structure, which is classified as a member of the B7 family due to the significant homology with B7 family members. The B7/CD28 superfamily provides both positive and negative co-signals to immunocytes in immune responses.

The interaction of ICOSLG with ICOS, the specific receptor for ICOSLG, is critically involved in the activation, proliferation, differentiation and cytokine production of T cells as well as in the antibody secretion from B cells during secondary immune responses.[4]

ICOSLG, which is extensively expressed in both non-lymphatic and lymphatic tissues, is an important molecule in upregulating and promoting T cell immune responses. Expression of ICOSLG in naive B cells and monocytes in PBMCs is at a low level. After stimulation by IFN-γ, TNF-α, or LPS, it can be quickly up-regulated. The induced expression of ICOS on activated T cells mainly regulates the secretion of Th2 cytokines and thus shifts the immune response to the Th2 type. It has been reported that the ICOS/ICOSLG pathway is involved in immunopathogenesis such as infection, hypersensitivity, autoimmune diseases, transplantation immunity and tumor immunity.

ICOSLG is also a major costimulator in endothelial cell-mediated T cell activation. It has an important physiological role of ICOSLG in the reactivation of effector/memory T cells on the endothelium controlling the entry of immune cells into inflamed tissue.[5]

Structure

Inducible costimulator-ligand (ICOS-L) is a member of the B7 family of costimulatory ligands[6] sharing 19–20% sequence identity with CD80 and CD86. Two splice variants of human ICOSLG have been described and designated hICOSLG and B7-H2/B7RP-1/hLICOS.[7]

Both molecules have an identical extracellular domain but differ at the carboxyl-terminal end of their cytoplasmic regions. In humans, cell surface expression of ICOSLG has been described on B cells, dendritic cells, monocytes/macrophages, and T cells. In addition, mRNA expression of ICOSLG has been detected in a variety of lymphoid and nonlymphoid organs, with hICOSLG showing a more lymphoid-restricted expression pattern (spleen, lymph node), whereas B7-H2/B7RP-1/hLICOSmRNA was expressed in all organs examined (e.g., spleen, kidney, heart, and brain).[8]

Interaction

Murine ICOSLG, unlike CD80 and CD86, does not interact with CD28 or CTLA-4 (CD152). Instead, ICOSLG binds to ICOS, a T cell-specific costimulatory molecule homologous to CD28 and CTLA-4.[9] In humans, ICOSLG binds to ICOS but also to CD28 and CTLA-4.[10]

The strong impact of ICOS/ICOSLG interaction on T cell-mediated immune responses in vivo became evident by the disruption of the ICOS gene in mice. ICOS deficient mice are characterized by impaired germinal center formation, have a profound defect in isotype class switching in T cell-dependent B cell responses, and are defective in IL-4 and IL-13 production. In addition, blockade of ICOS/ICOSLG interaction in animal models of experimental allergic encephalomyelitis and of cardiac allograft rejection revealed a critical role of ICOS and its ligand in inflammatory immune reactions.[5]

Immunodeficiencies

The research with mutant ICOSLG showed that if the protein was retained in ER/GA, instead of the cell surface in normal case, it diminished B cell costimulation of T cells. It led to defect in antibody and memory B cell generation. Mutant ICOSLG also impaired migration of lymphocytes and neutrophils across endothelial cells, which normally express ICOSLG. These defects contributed with altered adaptive immunity and neutropenia in patient, thus showing ICOSLG deficiency as a cause of combined immunodeficiency.[11]

Immunotherapy

The fluctuant balance between co-stimulatory and coinhibitory signals that a T cell receives participates in the initiation, effection, and termination of an immune response. Excessive activation and immune reaction of T cells may result in autoimmune diseases and host immune injury.

ICOSLG delivers a potent co-stimulatory signal to T cells when engaged by ICOS, resulting in T cell activation and proliferation. The existence of ICOS/ICOSLG signal in vivo is closely associated with many mouse autoimmune disease models. Conversely, the absence of ICOS/ICOSLG signal may be a good way to relieve autoimmune disease. In view of its critical function in regulating immunohomeostasis, ICOS signaling has aroused great attention in immunodiagnosis and therapy.[4]

The ICOS/ICOSLG axis has been shown to promote either antitumor T cell responses (when activated in Th1 and other Teff) or protumor responses when triggered in Tregs. Therefore, both agonistic and antagonistic monoclonal antibodies (mAbs) targeting this pathway are being investigated for cancer immunotherapy.[12]

Undoubtedly, the development of more efficient and specific monoclonal antibodies may be important for further disclosure of ICOSLG function. Agonistic Abs are currently being administered either alone or in combination with immunotherapy and chemotherapy.[13]

References list

  1. ↑ "Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro". DNA Research 5 (3): 169–176. June 1998. doi:10.1093/dnares/5.3.169. PMID 9734811. 
  2. ↑ "Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS". International Immunology 12 (10): 1439–1447. October 2000. doi:10.1093/intimm/12.10.1439. PMID 11007762. 
  3. ↑ "Entrez Gene: ICOSLG inducible T-cell co-stimulator ligand". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=23308. 
  4. ↑ 4.0 4.1 "Immunoreactivity of two novel monoclonal antibodies against human inducible co-stimulator ligand". Hybridoma 30 (4): 361–368. August 2011. doi:10.1089/hyb.2011.0014. PMID 21851236. 
  5. ↑ 5.0 5.1 "ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells". Proceedings of the National Academy of Sciences of the United States of America 99 (9): 6198–6203. April 2002. doi:10.1073/pnas.092576699. PMID 11983910. Bibcode: 2002PNAS...99.6198K. 
  6. ↑ "The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function". Nature Immunology 2 (3): 203–209. March 2001. doi:10.1038/85251. PMID 11224518. 
  7. ↑ "Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS". Blood 96 (8): 2808–2813. October 2000. doi:10.1182/blood.v96.8.2808.h8002808_2808_2813. PMID 11023515. 
  8. ↑ "Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules". Journal of Immunology 166 (12): 7300–7308. June 2001. doi:10.4049/jimmunol.166.12.7300. PMID 11390480. 
  9. ↑ "T-cell co-stimulation through B7RP-1 and ICOS". Nature 402 (6763): 827–832. December 1999. doi:10.1038/45582. PMID 10617205. Bibcode: 1999Natur.402..827Y. 
  10. ↑ "B7-h2 is a costimulatory ligand for CD28 in human" (in English). Immunity 34 (5): 729–740. May 2011. doi:10.1016/j.immuni.2011.03.014. PMID 21530327. 
  11. ↑ "Loss of human ICOSL results in combined immunodeficiency". The Journal of Experimental Medicine 215 (12): 3151–3164. December 2018. doi:10.1084/jem.20180668. PMID 30498080. 
  12. ↑ "Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy". Expert Opinion on Therapeutic Targets 22 (4): 343–351. April 2018. doi:10.1080/14728222.2018.1444753. PMID 29468927. 
  13. ↑ "The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy". ESMO Open 5 (1): e000544. January 2020. doi:10.1136/esmoopen-2019-000544. PMID 32516116. 

Further reading

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:ICOSLG&oldid=3594214"